Yes, good morning also from our side. We're here sitting in Duderstadt in the headquarter and happy to present our first nine months update.

We're looking back to a very successful nine months in 2025 and are with all our strategic core initiatives on track. Product launches and several acquisitions took place and are kicking off.

The strong core revenue growth continued in Q3 and leading to a year-to-date growth of 13.6% respectively 11.5% organic growth. This strong sales performance is reflected also in our profitability.

We have a substantial improvement of 3 percentage points in the underlying core EBITDA. Means a margin expansion to 24.3%.

This all leads to our guidance for 2025, which is narrowed to the upper half of 9 to 12%, a core underlying EBITDA margin of 25 to 26%, which is confirmed. At a glance, our numbers.

The core revenue is €1.158 billion, 13.6% growth, underlying EBITDA of €281 million and the EBITDA margin of 24.3%, and also a very positive free cash flow development, growth of 55%. In 2025, we launched several new products.

We have in the upper limb field, we launched a new platform with a new control system, Myo Plus, and terminal device platform, which allows all our upper limb products to be combinable with each other and switch. This is something we were looking forward very much, and this was launched mid of the year, and we do see quite a good track on this new technology.

In the lower limb prosthetic field, we launched the Taleo Adapt, which is a hydraulic ankle system specially designed for certain markets, first of all, the US market, where a certain reimbursement is in place, and also here, we have a lot of traction. Overall, we can see that especially in the foot segment, we are growing over market, with 20% year-to-date growth rate, meaning we're gaining market share there.

In the neuro-orthotic field, we have the C-Brace Interim launched, which means we're coming closer to the rehabilitation phase, we're coming closer to hospitals. That also means it's a higher conversion rate from people suffering from incomplete spinal cord injuries or stroke patients, which normally during the rehabilitation phase very often put in a wheelchair, we have now the chance to mobilize them from day one, which gives us access to a much bigger patient pool.

The new Exopulse suit generation, 9.5, is just launched now. We're now busy with sending out the new fit kits, does an improved operational function, we can install it better, more individual to certain patient groups.

Also here, we do expect access to larger patient population. On the exoskeleton side, we came out with the first powered exoskeleton, and which was very well accepted, we sold the first experience packages already to our key customers and had a very positive feedback from the market side.

Ongoing, of course, there are always product refinements, there are product updates. This is something what we're continuously doing and will continue also in the future.

On the M&A side, we invested in two technologies. Romedis, it's a technology specially designed for markets where we do have a lot of skilled labor.

Very often either emerging markets or markets where an extraordinary volume has to be handled with existing infrastructure. It enables CPOs or clinicians relatively fast and easy with a guaranteed quality outcome to fit patients with lower limb prosthetics.

Also, AXS is a technology in France, which has a certain reimbursement code. Also here, it's a new technology for lower limb prosthetics, how they're fitted to the patient.

On the B2C side, we managed to get two acquisitions completed, one in Belgium with Manon and one in Australia, Northern Prosthetics. Both were very good strategic fits regionally-wise, but also from the portfolio which we are serving.

Our venture investments, Onward Medical, we was now in October, but already done, we increased our stake in Onward Medical. Then we have Musclemetrics and Bionic Skin.

These are two spinoffs of MIT. Fantom Neuro, an Austin-based company.

All these venture investments are in new technologies, we are working towards the human-machine interface and having here now several options in order to be here frontrunner in new technologies. On the non-core portfolio, we divested already last year A4Access, a DME business, Cascade Orthopedic Supply, it's a distribution business in the US, and Active Life, California-based patient care entity.

Where we are still ongoing is our Human Mobility business, or the wheelchair business. We are in negotiations, ongoing negotiations, with certain candidates, and next year, we also will go further.

It's a smaller part of our business, the Ottobock Orthopedic Services, it's a billing service in the US, which we also will divest. That's so far from the business highlights.

I would now hand over to Arne Kreitz for the financial update.

Thank you, Oliver. I would like to guide us now through a little bit more detail through the financials.

Oliver already gave us an overview on the key financials. Just quick recap.

Very strong growth on the core revenue side with all-in 13.5%, which is driven by 11.5% of organic growth rate. Then we have 3% impact from M&A activities, negative 0.9% from FX impacts.

That's the bridge from the 11.5% to 13.6%. Underlying core EBITDA, we're looking into an increase of 3 percentage points in the profitability, in absolute terms €64 million additional EBITDA compared to last year.

Very strong improvement in performance. We're also seeing a very strong free cash flow performance, an absolute increase of €61 million, in relative terms 55% of an increase, so that means strong performance on the EBITDA side is also translating into cash.

I come to that in more detail on the next slides. Going deeper into the revenue side and breaking the revenue into our segments across the regions, on the EMEA side, we're looking at an organic growth rate of 9.7%, very consistent development also compared to last year.

The drivers are, as already discussed for the half-year financials, it's the innovations penetrating into the markets, it's new reimbursements that we have achieved like C-Brace reimbursement in France, and we are seeing continued impact of spike events. For example, Ukraine, volumes we see are picking up.

That's why EMEA is our largest region. It's an absolute contribution of €97 million an additional revenue, and that's all reflected in the 9.7% organic growth rate.

Americas, very strong pickup, and we're looking into 16% of organic growth rate, driven by strong performance on the B2B side. Again, innovations getting into the market, new reimbursements achieved on the C-Leg side.

We're seeing volumes doubling on that end. We're also seeing strong catch-up on the patient care side in the US.

As you might recall, we had a bit of a slower start at the beginning of the year and had been given the outlook that we're expecting a catch-up in the course of the year. We've been clearly seeing that in the third quarter with a growth rate which is, I think, in the area of 25%.

Very strong catch-up on the patient care side, and then all in all leads to 16% organic growth rate in Americas. Same picture in APAC.

We're looking at 16.5% organic growth driven by innovations getting into the developed markets like Australia and Japan, also positive development on the reimbursement side in those two markets. We're also seeing catch-up and build-up really of markets in the real emerging markets.

India is continuing to have a strong performance. That all reflects into the 16.5%.

Consistent, strong growth across the regions. It's not the one driver, it's not the one market, very consistent across the markets.

Looking into the revenue split across the B2B and B2C business, we are seeing strong performance on the B2B side with 17.1% organic growth, and that's consistent throughout the year. I repeat myself, driven by innovations getting into the markets.

X4 is penetrating really really well, but also the new reimbursements like K2 reimbursement in the US market, C-Brace reimbursement in the US market is continuing to be strong. France, we see first impacts of C-Brace reimbursement, Japan also.

Very, very strong growth on the B2B side. On the B2C side, we're looking into 4.7% of a growth.

Here, I'd like to recap that at the mid of the year, we have been standing at 2.9% of a organic growth rate on the patient care side. You can see the Q3 has across patient care been very strong, and it's also consistent to what we have been given as an explanation, slower start to the year, but we're expecting positive momentum throughout the year, and that's what we're seeing on the patient care side.

Underlying core EBITDA in more detail, already with the overview, we're looking into 24.3% overall profitability. What you can see across the regions is that we're seeing a nice catch-up of profitability across markets.

You can also see that the profitability has become much more consistent throughout the markets. We're looking into 24.4% in EMEA, 23.5% in Americas, 25.7% in APAC.

Also here, we had given you the outlook that we're expecting that profitabilities will normalize across markets, as also America is really catching up on the B2B side, but also on the patient care side. That's reflected in this consistent picture across the regional profitabilities.

Underlying drivers are also consistent throughout the year. We're looking into a strong gross profit development, which is driven by mix effects.

As higher components are driving the sales, they are higher in the relative gross margin. That's why that is cutting through.

We're seeing an underproportionate growth on the material cost side, also contributing to a better gross margin. We're seeing scale-up effects basically throughout the entire organization.

This high growth specifically on the B2B side leads to scale-up effects, which we're seeing on personal cost side, on the opex side, and that is driving profitability. Last but not least, we're also continuing to see that the efficiency measures that we're driving are giving us benefits.

Shared services in Bulgaria, we're continuing to ramp up. On manufacturing side in Bulgaria, we're continuing to ramp up, and that continuously is also benefiting on the profitability side.

Adjusted net income also very positive. You might have seen that on the underlying core EBITDA side, we are looking at an absolute increase of €64 million, and those €64 million are more or less translating into additional adjusted net income.

Additional adjusted net income in absolute terms is €53 million. That means the key driver is really the additional EBITDA that we're generating.

We're seeing benefits on the interest side, the lower net debt levels in combination with lowering interest rates are having positive benefits, while we are looking at slightly higher tax payments because of the better performance of the business. All in all, if I'm looking into how the EBITDA result is cutting through into the net income, we are looking into a very good translation.

One word on the adjustments, just as a recap, key adjustment items are really the cost of the IPO, which is a special item for this year, and the management participation program, which kind of runs until the IPO. That is an effect which is sizable.

Then the second impact is the impairment of €31 million on our Human Mobility business. You might recall we've been putting it as a asset held for sale mid-year 2025, and that's why that had an implication of an impairment of €31 million.

It's not new, but those two effects are the key drivers of the difference between adjusted net income and the final net income. Cash flow, very strong.

We're looking into an operating cash flow improvement of €72 million. Even stronger than what we've been seeing on the EBITDA side.

That's driven by the fact that in the EBITDA, there are some provisions included. The higher sales are leading to higher warranty provisions.

We partly have higher bonus provisions because of the better performance of the business than planned in the budget. That's why higher bonus provisions leading to an even higher operating cash flow than what we're seeing on the EBITDA side, which is then on the free cash flow side counterbalanced by capex investments.

They are also fully in line to what we had been communicating. R&D capitalization is at €30.5 million for the first nine months, and that is in line with what we had been communicating previously.

Finally, look into the leverage development. Here, we wanted to give you a bit the longer-term trending.

Also, you can see the very continuous improvement on the leverage side. Now, at the end of September, we're looking at 2.8 turns, and we had been given the guidance to 2.5 turns.

That is unchanged, probably will be ending slightly better. The overall trend driven by a reduction of the net debt level with the free cash flow that we're generating, we're now in the position that the net debt levels are starting to actively reduce, while at the same time the EBITDA is continuing to go up, and that's the underlying driver of the strong reduction on the leverage side, very happy development.

That leads me to the guidance update for 2025. Driven by the strong top-line performance that we've been seeing in the first nine months, we are narrowing our guidance to the upper half of the previously given guidance.

That means for the all-in core revenue growth, we're expecting 11.5 to 13%, for the organic core revenue growth, we're expecting 10.5 to 12%. That means we are very confident that the strong revenue growth that we've been seeing will also continue in Q4, although we have to say Q4 last year has also been having a good performance.

That's why we're narrowing the guidance to the upper end of our previously given guidance. Underlying core EBITDA margin is confirmed at 25 to 26%.

That's it in summary, and with that, like to open the round for questions.

Yeah. In the area of 2.5 to 3%.

I think you're referencing the EMEA region, right? It's 2.5 to 3% of the EMEA growth, which is driven by spike events.

Then the second question was, I think, on patient care North America performance. I think I mentioned it already, we're seeing a strong catch-up on the North America patient care performance.

In Q3, the growth has been above 25% organically. Q2 has already been strong, but we're really seeing a nice catch-up and gain of market share and now finalizing the integration.

That means, all in all, in the US, we're looking into a year-to-date patient care growth of more than 8%. As said, it's the combination of the normal market growth and the catch-up after the integration that we've been running through the last 2 years.

Plus, we installed a new CRM system, and we are generating really a lot of leads. This is also something which is fueling the pipeline.

Great. Very clear.

Thank you very much.

Maybe to the guidance. As we mentioned already during the management presentation, yeah, we are the new kids on the block, we have to earn your trust.

That's why our guidance is normally conservative. Yeah.

Underpromising, overdelivering, we would like to stay to the street, which we gave now, and yeah, hopefully, we can surprise you. This is something what we would like to continue, at least in the beginning.

Therefore, also for next year, we would like to confirm our guidance. That's for us important.

Regarding the Kinevo penetration, that's a continuously process. We are now 15 months in the process, so as I mentioned before, it's not that we're switching everybody.

The penetration will take until we have the full coverage will take 3, 4 years. That's why we're still seeing very positive and strong impact of the K2 reimbursement system in the USA.

I think the last question has been on the guidance for this year, why not more ambitious given the strong nine months trading. It's as I said, we had a strong Q4 also last year, and in general, the seasonality is that Q4 is always the strongest quarter of the year.

We've been running through our forecast three planning, and that leads us to the upper half of the previous guidance. I fully agree.

It's a strong momentum, but reflecting also strong performance in the last month of the last year, we are arriving at the upper half as just presented.

Yeah. To the Nairobi protocol, no, we haven't heard anything.

Our estimation that this will not change the current status quo is still there, but so the shutdown in the US, of course, is also having the impact there. I don't think that anybody the last 6 weeks worked on the documents.

Therefore, according to our information from the US, the earliest reaction which is expected will be April, May next year. Then on the acquisition side, yes, we have our pipeline, and we just yesterday had again our M&A meetings.

We are in several negotiations, and again, it's always a balanced approach, yeah, in technology, in patient care, but also maybe new technologies what we have seen from Onward. Therefore, yes, this is an ongoing process.

Regarding Onward, maybe Arne can give some updates. Yeah.

It's as Oliver said, we're following, as a recap, three buckets in M&A. One is on patient care, one is on product, one is on technology, and Onward fits into the technology bucket.

We believe that this is very complementary technology to what we're doing. We are working on shared product projects to see if we can expand the patient population that we are also reaching with our products, for example, C-Brace.

We believe that Onward is now at a stage where the technologies are starting to become to market with ARC-EX, and it's moving into the clinical phase with ARC-IM. Really interesting phase and a good timing to connect how our two competencies are working together.

That's why we have been participating in the refinancing round or the additional series financing round that Onward has been running through, and have been slightly increasing our share that we have now to at around 12% in Onward Medical.

Yeah. Also from our side, thanks a lot for joining and for the interest.

Summing it up, we are very satisfied with the performance in 2025 and looking forward for the next update. As I mentioned before, our guidance is conservative.

We think still it's an amazing trajectory we have and looking forward also a great opportunity. Thanks a lot, and yeah, talk to you soon.

Thank you.